Please assess the completion status of the following clinical trial:

Trial Title: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A (\< 1% FVIII)~* 30-45 years of age~* Previously treated subject (\> 100 Exposure days to any FVIII)~* On-demand therapy with any FVIII~Exclusion Criteria:~* No history of inhibitor~* No planned elective orthopedic surgery during the study duration (13 months)~* No severe concomitant disease~* No history of anaphylactic or other severe reaction to previous FVIII treatment

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- rFVIII-FS (octocog-alfa), (Kogenate FS) (Type: EXPERIMENTAL): On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).